Le Lézard2h
Boehringer Canada Announces Availability of SPEVIGO® for expanded indication in Canada
Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...
Hosted on MSN23h
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...
National Institute for Health and Care Excellence17h
In consultation: Guidance and quality standards
Proposed changes to appeal period for technology appraisal and highly specialised technologies appeals Methods / process manual consultation NICE process and methods 16 February 2025 Spesolimab for ...
Aussie property owners called to action over 'world's worst' invasive threat
Authorities have warned we could see 650,000 additional medical visits annually if the problem is not addressed.
Le Lézard2h
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic, ...
The American Journal of Managed Care19h
GPP Flares Linked to Increased Hospitalizations, Health Care Costs, Study Finds
New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
AnaptysBio’s (ANAB) Outperform Rating Reiterated at Wedbush
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research note issued to investors on Monday,RTT News reports. They ...